No abstract available.
Interferon-gamma Release Tests* ; Lupus Vulgaris*

No abstract available.
Humans ; Interferon-gamma Release Tests* ; Tuberculosis*

Limited data are available on which factors are associated with strong immunologic responses to T-SPOT.TB. We investigated the factors associated with strong positive responses in patients with extrapulmonary tuberculosis (E-TB). Of 173 patients with E-TB who gave positive results on T-SPOT.TB, 26 (15%) with a strong positive response (defined as > or =1,000 spot-forming units (SFU)/2.5x10(5) PBMC to ESAT-6 or CFP-10) and 71 (41%) with a low positive response (< or = 99 SFU (6-99 SFU)/2.5x10(5) PBMC) were further analyzed. Miliary TB was independently associated with a strong positive response to T-SPOT.TB, while advanced age and immunosuppression were independently associated with weak positive T-SPOT.TB responses.
Humans ; Immunosuppression ; Interferon-gamma Release Tests ; Tuberculosis*

In order to eliminate tuberculosis worldwide by 2050, effective management of latent tuberculosis infection is essential, and policy-makers have begun to recognize the importance of scaling up preventive therapy. The current guideline recommends targeted latent tuberculosis infection testing that identifies high-risk groups based on risk stratification for progression from latent infection to active disease. Both the tuberculin skin test and interferon-gamma releasing assay have a similar diagnostic efficacy for predicting progression to active tuberculosis. The Korean guideline recommends 9-month isoniazid monotherapy as the standard treatment; however, more evidence supports that short course rifampicin-based regimen is both more effective and tolerable than isoniazid monotherapy.
Diagnosis ; Interferon-gamma ; Interferon-gamma Release Tests ; Isoniazid ; Latent Tuberculosis ; Skin Tests ; Tuberculin ; Tuberculosis

BACKGROUND: The clinical manifestation of M. tuberculosis infection ranges from asymptomatic latent infection, to focal forms with minimal symptoms and low bacterial burdens, and finally to advanced tuberculosis (TB) with severe symptoms and high bacillary loads. We investigated the diagnostic sensitivity of the whole-blood interferon-gamma release assay according to the wide spectrum of clinical phenotypes. METHODS: In patients diagnosed with active TB that underwent QuantiFERON(R) (QFT) testing, the QFT results were compared with patients known to be infected with pulmonary tuberculosis (P-TB) and extra-pulmonary TB (EP-TB). In addition, the results of the QFT test were further analyzed according to the radiographic extent of disease in patients with P-TB and the location of disease in patients with EP-TB. RESULTS: There were no statistical differences in the overall distribution of QFT results between 177 patients with P-TB and 84 patients with EP-TB; the positive results of QFT test in patients with P-TB and EP-TB were 70.1% and 64.3%, respectively. Among patients with P-TB, patients with mild extents of disease showed higher frequency of positive results of QFT test than that of patients with severe form (75.2% vs. 57.1%, respectively; p=0.043) mainly due to an increase of indeterminate results in severe P-TB. Patients with TB pleurisy showed lower sensitivity by the QFT test than those with tuberculous lymphadenitis (48.8% vs. 78.8%, respectively; p=0.019). CONCLUSION: Although QFT test showed similar results between overall patients with P-TB and EP-TB, individual sensitivity was different according to the radiographic extent of disease in P-TB and the location of disease in EP-TB.
Humans ; Interferon-gamma ; Interferon-gamma Release Tests ; Pleurisy ; Tuberculosis ; Tuberculosis, Lymph Node ; Tuberculosis, Pulmonary

BACKGROUND: For the diagnosis of tuberculosis (TB), a variety of tests based on the patients' immune response has been introduced. We evaluated the clinical usefulness of combined anti-tuberculosis antibody (anti-TB Ab) test and Interferon-gamma release assay (IGRA), evaluating humoral and cellular immune response to Mycobacterium tuberculosis, respectively. METHODS: Among patients tested for IGRA, 78 patients diagnosed as TB and treated with anti-TB drug and 80 non-TB patients were included in this study. We used QuantiFERON-TB GOLD (QFT, Cellestis limited, Australia) for IGRA and an immunochromatographic assay, Easy Test TB (ASAN PHARM, Korea), for anti-TB Ab test. RESULTS: The sensitivity, specificity, and positive and negative predictive values of Easy Test TB were 23.1%, 98.8%, 94.7% and 56.8%, respectively. QFT had a significantly higher sensitivity than Easy Test TB (67.9% vs. 23.1%; P<0.05). The agreement between the two assays was poor (69.6%, k=0.190). Of the 18 cases with positive Easy Test TB, six (33%) showed negative QFT results. The combination of Easy Test TB and QFT had a significantly higher sensitivity than single QFT (75.6%, vs. 67.9%; P=0.031). CONCLUSIONS: The combination of Easy Test TB and QFT could be used to aid in a rapid diagnosis and early treatment of TB.
Humans ; Immunity, Cellular ; Immunochromatography ; Interferon-gamma ; Interferon-gamma Release Tests ; Mycobacterium tuberculosis ; Sensitivity and Specificity ; Tuberculosis

Here, we report a case in which the rapid diagnosis of tuberculous pericarditis was made using Mycobacterium tuberculosis (MTB)-specific interferon-gamma release assay on peripheral blood and pericardial effusion. Acid-fast bacilli staining, mycobacterial culture, and nucleic acid amplification targeting MTB using pericardial fluid were negative. However, elevated adenosine deaminase (ADA) activity in pericardial fluid and interferon-gamma release assay positivity in both pericardial fluid and peripheral blood indicated the presence of tuberculous pericarditis. After anti-tuberculous and steroid treatment, the patient's clinical symptoms improved, and pericardial effusion has not reoccurred.
Adenosine Deaminase ; Diagnosis* ; Interferon-gamma Release Tests* ; Interferon-gamma* ; Mycobacterium tuberculosis ; Pericardial Effusion ; Pericarditis, Tuberculous*

T-SPOT. TB is an interferon-gamma release assay to detect T-cell response to early secreting antigen target 6 and culture filtrate protein 10 peptides by enzyme-linked immunospot assay for tuberculosis diagnosis. It is highly sensitive and specific, and will not be affected by the subject's immune status and Bacillus Calmette-Guerin vaccination. This assay has been licensed for in-vitro diagnosis in Europe and the United States. Its potential roles in distinguishing active tuberculosis from latent tuberculosis infection and predicting active tuberculosis among individuals with latent tuberculosis have been increasingly studies. This article reviews the advances in the clinical application of T-SPOT. TB.
Humans ; Interferon-gamma ; Interferon-gamma Release Tests ; Mycobacterium tuberculosis ; T-Lymphocytes ; Tuberculosis ; diagnosis

OBJECTIVETo evaluate the sensitivity of an interferon-gamma release assay T-SPOT. TB in the diagnosis of bacteriologically or histologically confirmed extrapulmonary tuberculosis.

METHODTotally 31 patients with bacteriologically or histologically confirmed extrapulmonary tuberculosis in Peking Union Medical College Hospital received T-SPOT. TB assay to detect early secreting antigen target 6 or culture filtrate protein 10 peptides-specific T cells in the peripheral blood mononuclear cells (PBMCs).

RESULTST-SPOT. TB assay showed positive results in 29 patients with extrapulmonary tuberculosis and the sensitivity was 93.5% (95% CI 84.8% - 100%). The median of spot forming cells (SFCs) in response to early secreting antigen target 6 peptides was 196/10(6) PBMCs (interquartile range, 72-532/10(6) PBMCs), the median of SFCs in response to culture filtrate protein 10 peptides was 276 SFCs/10(6) PBMCs (interquartile range, 72-568/10(6) PBMCs), and the median of the incorporate SFCs was 612/10(6) PBMCs (interquartile range, 192-1 152/10(6) PBMCs).

CONCLUSIONT-SPOT. TB is highly sensitive in diagnosing extrapulmonary tuberculosis.

BACKGROUND: QuantiFERON(R)-TB Gold In Tube (QFT-G IT) has been used for diagnosing latent tuberculosis infection and active tuberculosis (TB) since 2007. However, there has not been enough data on QFT-G IT for universal use in children. In this study, we evaluated the clinical usefulness of the QFT-G IT in pediatric practice. METHODS: We retrospectively reviewed the clinical records of 70 patients younger than 18 years of age who had taken QFT-G IT and had a tuberculin skin test (TST) between July 2007 and July 2009 at Wonju Christian Hospital. The subjects were divided into two groups, asymptomatic TB exposure group and disease group. Four patients who were taking immunosuppressants during the study period were excluded. RESULTS: A total of 66 immunocompetent children were included in this study. Among 27 asymptomatic children who had contact histories of TB, 6 (22.2%) were found to be positive by QFT-G IT. Eleven (40.7%) and 5 (18.5%) children were found to be positive by TST with cutoff values of > or =5 mm and > or =10 mm, respectively. Agreement was fair to good between QFT-G IT and TST (kappa=0.59: cutoff value > or =5 mm, kappa=0.7: cutoff value > or =10 mm). In disease group, 14 patients (35.9%) were diagnosed with active tuberculosis, 8/14 (57.1%) were positive on TST and 9/14 (64.3%) on QFT-G IT. The positive rate of acid-fast bacilli smear, TB-polymerase chain reaction, and culture for tuberculosis was 11% (1/9), 27.3% (3/11) and 33.3% (3/9), respectively. CONCLUSION: Our data support that the QFT-G IT can be used as an additional diagnostic tool for latent and active tuberculosis infection in children.
Child ; Collodion ; Humans ; Immunosuppressive Agents ; Interferon-gamma ; Interferon-gamma Release Tests ; Latent Tuberculosis ; Retrospective Studies ; Skin Tests ; Tuberculin ; Tuberculosis